Can Psilocybin Treat Obesity? New Evidence, Future Directions

The potential use of serotonergic psychedelic drugs has yet to be explored for treatment of multimodal health issues such as obesity. A new preclinical study aims to explore the effects of psilocybin in rodent food consumption and weight gain.


Empty Calories: Medication Options for the Obesity Epidemic

Obesity is a worldwide health concern – the World Health Organization reports 39% of adults globally are overweight, and 13% are considered obese.1 While the cause of obesity is still debated,2–4 medical professionals agree that the condition is a multifaceted health disorder with contributing genetic, psychological, and environmental factors leading to consequential secondary health concerns.5–7

Medications that address this widespread health concern are few and far between. While newer drugs such as semaglutide and tirzepatide which mimic specific hormones are promising approaches to weight loss,8 there are few drugs presently approved for this primary use. Historically, treatment tactics have ranged from prescription amphetamines (that come along with a high risk of dependence and addiction) to amphetamine-like drugs, which stimulate norepinephrine release (such as phentermine).9,10 These drugs, however, can result in serious and undesirable side effects and have a high risk of abuse – thus, they are now rarely prescribed for obesity and weight-loss indications.

The mid-century development of the serotonergic (5-HT) agonist fenfluramine showed promise as an effective obesity treatment.10 Preclinical investigations identified that fenfluramine acts as an agonist at 5-HT1B and 5-HT2C receptors,11  with 5-HT2C activation thought to give rise to its appetite-suppressing effects.9,12  Clinically, fenfluramine can induce cardiac side effects and was linked with the development of valvular heart disease following chronic 5-HT2B activation.13 Thus, fenfluramine is no longer used as a treatment for obesity. However, the importance of 5-HT receptors in food-related behaviors and appetite suppression has reemerged as a point of interest in psychedelic research. Serotonergic psychedelics may be desirable drug targets for obesity treatment without the undesirable side effects and risk of developing valvular heart disease.

Psilocybin as a Novel Obesity Treatment

A new preclinical study from Alasdair M. Barr’s laboratory at the University of British Columbia investigated the effects of psilocybin on high-fat diet food consumption and weight gain.14 This study (funded by Neonmind Biosciences) used a male rat model of obesity to determine the efficacy of psilocybin (at 0.1 mg/kg, 1.0 mg/kg, and 5 mg/kg doses) to reduce high-fat, high-sugar “cafeteria diet” food consumption and body weight (Figure 1). Psilocybin was compared with a positive control drug metformin, which is commonly prescribed to overweight patients with prediabetes or type 2 diabetes and regulates the body’s insulin secretion, subsequently reducing sugar (glucose) levels in the blood.

Prior to beginning the drug treatment regimen, blood tests were taken to measure baseline glucose levels. 27 days of drug treatment (psilocybin or metformin) were combined with daily body weight and food intake tracking, as well as another blood test to measure glucose levels halfway through treatment (day 10-11). After drug treatments were completed, a glucose tolerance test was performed. This test is a commonly used method of determining how consumed glucose is metabolized by the body through measuring circulating levels at various time points post-consumption. Additionally, dissection of fat pads was performed at the end of the study for analysis of fat tissue and to determine if psilocybin or metformin treatments had any effect on tissue volume and specific tissue types.

Figure 1. Study timeline illustrating flow of the experimental protocol used for investigating psilocybin’s potential for obesity treatment. Male rats were fed a high-fat diet until weights reached the desired target of ~600 grams, followed with blood collection to measure circulating glucose levels. Drug treatment with psilocybin (0.1 mg/kg, 1.0 mg/kg [excluded due to experimental error], and 5.0 mg/kg) or metformin (300 mg/kg) or control saline injections commenced for 27 days, with daily weight and food intake tracking and another blood sample of glucose levels at 10-11 days into treatment. After 27 days, rats underwent glucose tolerance testing, with injections of glucose and blood sampling at multiple timepoints. The experiment finished with dissection and collection of adipose tissue. Adapted from Huang et al. 2022 by Juliet Meccia, created with

The 1.0 mg/kg psilocybin group was excluded due to drug administration error, leaving the low-dose (0.1 mg/kg) and high-dose (5.0 mg/kg) psilocybin treatment groups for final analysis. The sizeable difference in drug dose between these two groups coupled with the current precedent in preclinical research to use 1.0 mg/kg of psilocybin as an effective dose leaves a gap in our ability to interpret how a typical dose of psilocybin may alter weight gain and high-fat food consumption.15,16

Male rats fed the high-calorie cafeteria diet and who received saline injections showed the highest rate of weight gain, with an average of ~6% body weight change compared with their starting weight. By comparison, control rats fed a normal laboratory diet and receiving saline injections only had an average ~4% increase in body weight compared with their baseline. Compared to animals receiving non-drug injections of saline, both psilocybin doses were efficacious at decreasing weight-gain in rats fed a cafeteria diet – the groups given 0.1 mg/kg and 5.0 mg/kg of psilocybin respectively showed averages of ~5% and ~4.5% body weight changes, compared to their starting weights. Rats fed a high-calorie diet and treated with metformin exhibited the greatest changes in relative body weight, with an average ~3% change.

Due to the formulation of the high-calorie diet, it was not possible to determine whether animals treated with psilocybin or metformin showed preference towards specific macronutrients – this would prove an interesting follow-up, and would contribute to our understanding of how pharmacologically different treatments for obesity may alter food-intake behavior in regards to specific types of nutrients (for example, fats versus sugars).

Measurement of fasting glucose levels (a type of test used typically to monitor blood glucose in absence of consumed food and useful in diagnosing diabetes) midway through drug treatment did not reveal any significant differences between glucose levels of rats treated with saline, either dose of psilocybin, or metformin. This may have been due to the lack of overall impact of the high-fat diet on the animals’ blood sugar dysregulation. Comparison of fasting glucose levels for control high-calorie diet rats compared with those of the control normal-calorie diet group revealed only a slight increase in fasting glucose levels of the former group. While blood glucose dysregulation is commonly associated with co-occurring obesity and diabetes, the authors are careful to point out that this specific animal model is most appropriate for obesity only.

Dissection of fat tissue to measure differences in tissue weight showed significant differences in the subcutaneous fat of all high-fat diet versus normal-diet animals, except for those treated with metformin. Analysis of fat tissue from behind the abdomen revealed that animals fed a normal-calorie diet as well as those on high-fat diets treated with 5.0 mg/kg psilocybin and metformin had overall lower amounts of fat tissue from this area. Psilocybin and metformin do not share a similar pharmacological profile – the discovery that both drugs reduced this specific type of fat tissue warrants further research. Repeating this experiment with inclusion of the 1.0 mg/kg psilocybin treatment group would be informative as to whether this moderate dose has similar fat tissue reduction capabilities. Expanding the scope of this work to include female rodents is also necessary to ensure fully-encompassing and translatable findings.

Systemic or Psychological?

The focus of Huang and colleagues’ new research was to determine the systemic effects of psilocybin on weight gain, blood glucose levels, and accumulated fat tissue. These health-related aspects of obesity are important and may be predictive of disease outcomes.17,18 But what about the psychological and psychiatric factors that contribute to obesity? While preclinical investigations of such factors are limited in scope, human clinical work has established that psilocybin induces long-lasting and positive changes in mood, affect, and perspectives in both healthy participants and patients with psychiatric illnesses such as depression.19–23 Clinical research looking at psilocybin treatment for obesity is lacking but it is possible that the drug may alter complex neural circuits linked with mood, affect, motivation, and reward.

Future preclinical investigations can incorporate behavioral measures of affect and food consumption with changes in neural plasticity processes to see how psilocybin might alter brain connectivity and drive changes in mood and eating habits. Human clinical studies should include psychological measures to determine how the drug might be altering self-image and include patients with co-morbid psychiatric illnesses commonly linked with obesity.24,25 Lastly, findings from preclinical research that psilocybin triggers neural processes promoting new and lasting connections between neurons can be translated into human studies by tracking any drug-induced changes in learned patterns of food intake and eating behaviors.

Through incorporating a rat model of obesity with psilocybin drug treatment testing, Huang and colleagues put forth exciting new research exploring the potential for serotonergic psychedelics to treat systemic health conditions. Their findings that repeated psilocybin injections reduce overall high-fat food consumption and prevent weight gain pave the path for future preclinical research investigating more complex food-related behaviors and potential neural mechanisms at play. Undoubtedly, this work will soon be brought into the sphere of clinical research, where psilocybin’s ability to treat both systemic manifestations of obesity and contributing psychological factors can truly be tested.


Notify of

Inline Feedbacks
View all comments
  1. Obesity and overweight. Accessed July 22, 2022.
  2. Wilding JPH, Mooney V, Pile R. Should obesity be recognised as a disease? BMJ. Published online July 17, 2019:l4258. doi:10.1136/bmj.l4258
  3. Wright SM, Aronne LJ. Causes of obesity. Abdom Radiol. 2012;37(5):730-732. doi:10.1007/s00261-012-9862-x
  4. Conway B, Rene A. Obesity as a disease: no lightweight matter. Obes Rev. 2004;5(3):145-151. doi:10.1111/j.1467-789X.2004.00144.x
  5. van Dijk SJ, Molloy PL, Varinli H, et al. Epigenetics and human obesity. Int J Obes. 2015;39(1):85-97. doi:10.1038/ijo.2014.34
  6. Dallman MF. Stress-induced obesity and the emotional nervous system. Trends in Endocrinology & Metabolism. 2010;21(3):159-165. doi:10.1016/j.tem.2009.10.004
  7. Hebebrand J, Hinney A. Environmental and Genetic Risk Factors in Obesity. Child and Adolescent Psychiatric Clinics of North America. 2009;18(1):83-94. doi:10.1016/j.chc.2008.07.006
  8. Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Drugs for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113-1132. doi:10.1007/s40265-018-0946-y
  9. Vickers S, Dourish C, Kennett G. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology. 2001;41:200-209. doi:10.1016/S0028-3908(01)00063-6
  10. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: A Review of its Pharmacological Properties and Therapeutic Efficacy in Obesity. Drugs. 1975;10(4):241-323. doi:10.2165/00003495-197510040-00001
  11. Vickers S, Clifton P, Dourish C, Tecott L. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology (Berl) 143: 309-314. Psychopharmacology. 1999;143:309-314. doi:10.1007/s002130050952
  12. Porter RHP, Benwell KR, Lamb H, et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol. 1999;128(1):13-20. doi:10.1038/sj.bjp.0702751
  13. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588. doi:10.1056/NEJM199708283370901
  14. Huang J, Pham M, Panenka WJ, Honer WG, Barr AM. Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. Frontiers in Psychiatry. 2022;13. Accessed July 22, 2022.
  15. Shao LX, Liao C, Gregg I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-2544.e4. doi:10.1016/j.neuron.2021.06.008
  16. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118(17):e2022489118. doi:10.1073/pnas.2022489118
  17. Dixon JB. The effect of obesity on health outcomes. Molecular and Cellular Endocrinology. 2010;316(2):104-108. doi:10.1016/j.mce.2009.07.008
  18. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004;53(8):2095-2100. doi:10.2337/diabetes.53.8.2095
  19. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268-283. doi:10.1007/s00213-006-0457-5
  20. Doss MK, Považan M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11(1):574. doi:10.1038/s41398-021-01706-y
  21. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285
  22. Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10(1):2214. doi:10.1038/s41598-020-59282-y
  23. Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research. 2020;284:112749. doi:10.1016/j.psychres.2020.112749
  24. Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health. 2000;90(2):251-257.
  25. Anderson SE, Cohen P, Naumova EN, Jacques PF. Adolescent obesity and risk for subsequent major depressive disorder and anxiety disorder: prospective evidence. Psychosomatic Medicine. Published online 2007:740-747.